Annual EBITDA:
-$72.99M+$64.10M(+46.76%)Summary
- As of today, GLUE annual EBITDA is -$72.99 million, with the most recent change of +$64.10 million (+46.76%) on December 31, 2024.
- During the last 3 years, GLUE annual EBITDA has fallen by -$2.24 million (-3.17%).
- GLUE annual EBITDA is now -852.02% below its all-time high of -$7.67 million, reached on December 31, 2019.
Performance
GLUE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$30.88M-$17.45M(-129.95%)Summary
- As of today, GLUE quarterly EBITDA is -$30.88 million, with the most recent change of -$17.45 million (-129.95%) on September 30, 2025.
- Over the past year, GLUE quarterly EBITDA has dropped by -$6.46 million (-26.43%).
- GLUE quarterly EBITDA is now -167.01% below its all-time high of $46.08 million, reached on March 31, 2025.
Performance
GLUE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$16.84M-$6.46M(-27.71%)Summary
- As of today, GLUE TTM EBITDA is $16.84 million, with the most recent change of -$6.46 million (-27.71%) on September 30, 2025.
- Over the past year, GLUE TTM EBITDA has increased by +$137.91 million (+113.91%).
- GLUE TTM EBITDA is now -27.71% below its all-time high of $23.30 million, reached on June 30, 2025.
Performance
GLUE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GLUE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +46.8% | -26.4% | +113.9% |
| 3Y3 Years | -3.2% | -19.8% | +117.4% |
| 5Y5 Years | -852.0% | -396.9% | +206.8% |
GLUE EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -3.2% | +46.8% | -167.0% | +13.8% | -27.7% | +112.3% |
| 5Y | 5-Year | -852.0% | +46.8% | -167.0% | +13.8% | -27.7% | +112.3% |
| All-Time | All-Time | -852.0% | +46.8% | -167.0% | +13.8% | -27.7% | +112.3% |
GLUE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$30.88M(-130.0%) | $16.84M(-27.7%) |
| Jun 2025 | - | -$13.43M(-129.1%) | $23.30M(+279.2%) |
| Mar 2025 | - | $46.08M(+205.9%) | $6.14M(+108.4%) |
| Dec 2024 | -$72.99M(+46.8%) | $15.06M(+161.7%) | -$72.99M(+39.7%) |
| Sep 2024 | - | -$24.42M(+20.1%) | -$121.07M(+8.1%) |
| Jun 2024 | - | -$30.58M(+7.5%) | -$131.78M(+3.8%) |
| Mar 2024 | - | -$33.05M(-0.1%) | -$137.03M(+0.0%) |
| Dec 2023 | -$137.09M(-26.2%) | -$33.02M(+6.0%) | -$137.09M(-2.4%) |
| Sep 2023 | - | -$35.13M(+1.9%) | -$133.88M(-7.5%) |
| Jun 2023 | - | -$35.83M(-8.2%) | -$124.53M(-9.5%) |
| Mar 2023 | - | -$33.11M(-11.1%) | -$113.76M(-9.6%) |
| Dec 2022 | -$108.64M | -$29.81M(-15.6%) | -$103.83M(-7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$25.79M(-2.9%) | -$96.60M(-7.2%) |
| Jun 2022 | - | -$25.06M(-8.2%) | -$90.10M(-9.0%) |
| Mar 2022 | - | -$23.17M(-2.6%) | -$82.69M(-16.9%) |
| Dec 2021 | -$70.75M(-157.5%) | -$22.58M(-17.1%) | -$70.75M(-46.9%) |
| Sep 2021 | - | -$19.29M(-9.2%) | -$48.17M(-37.2%) |
| Jun 2021 | - | -$17.66M(-57.2%) | -$35.10M(-54.2%) |
| Mar 2021 | - | -$11.23M(-80.7%) | -$22.77M(-44.5%) |
| Dec 2020 | -$27.47M(-258.3%) | - | - |
| Sep 2020 | - | -$6.21M(-16.7%) | -$15.76M(-65.1%) |
| Jun 2020 | - | -$5.32M(-26.1%) | -$9.55M(-126.1%) |
| Mar 2020 | - | -$4.22M | -$4.22M |
| Dec 2019 | -$7.67M | - | - |
FAQ
- What is Monte Rosa Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Monte Rosa Therapeutics, Inc.?
- What is Monte Rosa Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Monte Rosa Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Monte Rosa Therapeutics, Inc.?
- What is Monte Rosa Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Monte Rosa Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Monte Rosa Therapeutics, Inc.?
- What is Monte Rosa Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Monte Rosa Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of GLUE is -$72.99M
What is the all-time high annual EBITDA for Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. all-time high annual EBITDA is -$7.67M
What is Monte Rosa Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, GLUE annual EBITDA has changed by +$64.10M (+46.76%)
What is Monte Rosa Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of GLUE is -$30.88M
What is the all-time high quarterly EBITDA for Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. all-time high quarterly EBITDA is $46.08M
What is Monte Rosa Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, GLUE quarterly EBITDA has changed by -$6.46M (-26.43%)
What is Monte Rosa Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of GLUE is $16.84M
What is the all-time high TTM EBITDA for Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. all-time high TTM EBITDA is $23.30M
What is Monte Rosa Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, GLUE TTM EBITDA has changed by +$137.91M (+113.91%)